Duffy Phenotype Does Not Influence the Clinical Severity of Sickle Cell Disease
Authors:
- S.O. KeliSKS.O. Keli
- R.A. PietersRPR.A. Pieters
- R.A. RojerRRR.A. Rojer
- A.J. DuitsADA.J. Duits
- 1 September 2000
- journal article
- Published by Elsevier in Clinical Immunology
- Vol. 96 (3) , 264-268
Abstract
No abstract availableKeywords
This publication has 19 references indexed in Scilit:
- Neutrophil activation in sickle cell diseaseJournal of Leukocyte Biology, 1999
- Up-regulation of Duffy antigen receptor expression in children with renal diseaseKidney International, 1999
- Elevated IL‐8 levels during sickle cell crisisEuropean Journal of Haematology, 1998
- Insights into the Structure and Function of Membrane Polypeptides Carrying Blood Group AntigensVox Sanguinis, 1998
- Chemokines: leucocyte recruitment and activation cytokinesThe Lancet, 1997
- Mutations in the erythrocyte chemokine receptor (Duffy) gene: the molecular basis of the Fya/Fyb antigens and identification of a deletion in the Duffy gene of an apparently healthy individual with the Fy(a – b–) phenotypeBritish Journal of Haematology, 1995
- The Duffy antigen/receptor for chemokines (DARC) is expressed in endothelial cells of Duffy negative individuals who lack the erythrocyte receptor.Journal of Experimental Medicine, 1995
- Red blood cells are a sink for interleukin 8, a leukocyte chemotaxin.Journal of Clinical Investigation, 1991
- Pain in Sickle Cell DiseaseNew England Journal of Medicine, 1991
- Erythrocyte Adherence to Endothelium in Sickle-Cell AnemiaNew England Journal of Medicine, 1980